Creative Medical Technology Holdings, Inc. (CELZ) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Creative Medical Technology Holdings, Inc. (CELZ) Healthcare & Pipeline Overview

Creative Medical Technology Holdings, Inc. is a biotechnology firm specializing in adult stem cell therapies for various conditions, including erectile dysfunction and infertility. With a small team and a focus on regenerative medicine, the company operates in a competitive landscape of larger, more established biotechnology companies.

What Is the Investment Thesis for CELZ?

Investing in Creative Medical Technology Holdings, Inc. presents a high-risk, high-reward scenario. The company's focus on adult stem cell therapies targets significant unmet medical needs, offering substantial potential upside if clinical trials are successful and products gain regulatory approval. However, the company's small market capitalization of $0.01 billion and negative profit and gross margins of -192066.3% and -3986.6%, respectively, indicate significant financial challenges. The company's success hinges on its ability to secure funding, navigate regulatory hurdles, and demonstrate clinical efficacy. Key catalysts include successful clinical trial outcomes for its pipeline products and strategic partnerships. The high beta of 1.85 suggests significant volatility, making this investment suitable only for risk-tolerant investors.

Based on FMP financials and quantitative analysis

CELZ Key Highlights

Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.

• Negative profit margin of -192066.3% reflects substantial ongoing losses and the need for significant revenue generation.
• Negative gross margin of -3986.6% indicates that the cost of goods or services exceeds revenue, highlighting operational inefficiencies.
• Beta of 1.85 suggests the stock is more volatile than the market, potentially offering higher returns but also greater risk.
• The company focuses on adult stem cell treatments, a rapidly evolving field with potential for breakthrough therapies but also regulatory uncertainty.

Who Are CELZ's Competitors?

CELZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CELZ's Key Strengths?

Proprietary stem cell technologies.

• Diverse pipeline of treatments targeting multiple conditions.
• Potential for breakthrough therapies in unmet medical needs.
• Focus on regenerative medicine, a growing field.

What Are CELZ's Weaknesses?

Small market capitalization and limited financial resources.

• Negative profit and gross margins.
• Dependence on successful clinical trials and regulatory approvals.
• Small team and limited infrastructure.

What Could Drive CELZ Stock Higher?

Clinical trial results for CaverStem in treating erectile dysfunction.

• Clinical trial results for FemCelz in treating female sexual dysfunction.
• Clinical trial results for StemSpine in treating chronic lower back pain.
• Clinical trial results for ImmCelz in treating stroke patients.
• Clinical trial results for OvaStem in treating female infertility.

What Are the Key Risks for CELZ?

Financial-distress signal — its Altman Z-Score of -9.79 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-81.2%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Clinical trial failures could significantly impact the company's valuation.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from larger biotechnology and pharmaceutical companies.
• Difficulty securing funding to support research and development.
• The company's small size and limited resources pose operational challenges.

What Are the Growth Opportunities for CELZ?

• CaverStem, Creative Medical Technology Holdings's treatment for ED, could capture a significant share of this market if it proves to be a safe and effective alternative to existing treatments like PDE5 inhibitors. The timeline for market entry depends on successful clinical trials and regulatory approval, potentially within the next 3-5 years. A key competitive advantage would be a novel mechanism of action or improved efficacy compared to existing therapies.
• FemCelz for Female Sexual Dysfunction: Female sexual dysfunction, including loss of genital sensitivity and dryness, represents a significant unmet medical need. FemCelz targets this market, which is estimated to be substantial given the prevalence of these conditions. Successful development and commercialization of FemCelz could provide Creative Medical Technology Holdings with a first-mover advantage in this space. The timeline for market entry depends on clinical trial outcomes and regulatory approval, with potential launch in 3-5 years. A key differentiator would be demonstrating significant improvement in sexual function and quality of life for women.
• StemSpine for Chronic Lower Back Pain: Chronic lower back pain is a widespread and debilitating condition, creating a large market for effective treatments. StemSpine, Creative Medical Technology Holdings's therapy for chronic lower back pain, aims to address this need. The market for pain management is substantial, and a successful stem cell therapy could capture a significant portion of it. The timeline for market entry depends on clinical trial results and regulatory approval, potentially within 4-6 years. A key competitive advantage would be demonstrating long-term pain relief and functional improvement.
• ImmCelz for Stroke Patients: Stroke is a leading cause of disability, and there is a significant need for therapies that can improve outcomes for stroke patients. ImmCelz, Creative Medical Technology Holdings's treatment for stroke, targets this critical area. The market for stroke rehabilitation and recovery is substantial, and a successful stem cell therapy could have a significant impact. The timeline for market entry depends on clinical trial success and regulatory approval, potentially within 5-7 years. A key differentiator would be demonstrating improved neurological function and reduced disability in stroke patients.
• OvaStem for Female Infertility: Female infertility affects a significant percentage of women, creating a substantial market for fertility treatments. OvaStem, Creative Medical Technology Holdings's therapy for female infertility, aims to address this need. The market for assisted reproductive technologies is growing, and a successful stem cell therapy could offer a novel approach to treating infertility. The timeline for market entry depends on clinical trial outcomes and regulatory approval, potentially within 4-6 years. A key competitive advantage would be demonstrating improved egg quality and increased pregnancy rates.

What Opportunities Does CELZ Have?

• Partnerships with larger pharmaceutical companies.
• Out-licensing of its technologies.
• Expansion into new therapeutic areas.
• Positive clinical trial results leading to regulatory approvals.

What Are CELZ's Competitive Advantages?

• Proprietary stem cell technologies.
• Patents protecting its treatment methods.
• First-mover advantage in specific niche markets (if therapies are approved).
• Potential for strong brand recognition if treatments prove effective.

What Does CELZ Do?

Creative Medical Technology Holdings, Inc., founded to advance regenerative medicine, is a biotechnology company headquartered in Phoenix, Arizona. The company focuses on developing and commercializing adult stem cell treatments across several therapeutic areas, including immunology, urology, orthopedics, and neurology. Its core product pipeline includes CaverStem, a treatment for erectile dysfunction; FemCelz, designed to address loss of genital sensitivity and dryness in women; StemSpine, a therapy for chronic lower back pain; ImmCelz, targeting stroke patients; and OvaStem, intended to treat female infertility. The company's approach leverages adult stem cell technology to potentially offer innovative solutions for conditions with unmet medical needs. Creative Medical Technology Holdings, Inc. aims to establish a presence in the regenerative medicine market through its research and development efforts. The company's operations are primarily based in the United States, and it is working to navigate the regulatory landscape to bring its products to market. With a small team, Creative Medical Technology Holdings, Inc. faces the challenge of competing with larger, more established biotechnology companies that have greater resources and broader product portfolios.

What Products and Services Does CELZ Offer?

• Develop adult stem cell treatments for various medical conditions.
• Focus on regenerative medicine in immunology, urology, orthopedics, and neurology.
• Offer CaverStem for the treatment of erectile dysfunction.
• Offer FemCelz for the treatment of loss of genital sensitivity and dryness in women.
• Offer StemSpine for the treatment of chronic lower back pain.
• Offer ImmCelz for the treatment of stroke patients.
• Offer OvaStem for the treatment of female infertility.

How Does CELZ Make Money?

• Develops and patents stem cell-based therapies.
• Seeks regulatory approval for its treatments.
• Aims to commercialize its products through partnerships or direct sales.
• Generates revenue through licensing agreements or product sales upon approval.

What Industry Does CELZ Operate In?

Creative Medical Technology Holdings, Inc. operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The regenerative medicine market, which includes stem cell therapies, is projected to grow significantly, driven by increasing demand for innovative treatments for chronic diseases and age-related conditions. However, the company faces competition from larger, more established biotechnology and pharmaceutical companies with greater resources and broader product portfolios. Success in this industry requires strong intellectual property, successful clinical trials, and effective commercialization strategies.

Who Are CELZ's Key Customers?

• Patients suffering from erectile dysfunction (CaverStem).
• Women experiencing loss of genital sensitivity and dryness (FemCelz).
• Individuals with chronic lower back pain (StemSpine).
• Stroke patients seeking improved recovery (ImmCelz).
• Women experiencing infertility (OvaStem).

Company Profile

Creative Medical Technology Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Phoenix, United States.

Return on equity for Creative Medical Technology Holdings, Inc. stands at -81.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -50.2%, showing how much profit it generates from its asset base. A current ratio of 19.69 indicates the company holds enough short-term assets to cover its near-term obligations.

CELZ Valuation & Market Position

Relative to its peer group, CELZ's quantitative score of 18/100 is below the peer average of 79/100.

Quarterly Financial Performance: Creative Medical Technology Holdings, Inc.

Revenue for Creative Medical Technology Holdings, Inc. came in at $0 during Jun 2026. The company recorded a net loss of $1.5M, with diluted EPS of $-0.41. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, CELZ averaged $-0.51 in diluted EPS.

Creative Medical Technology Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.79 places it in the distress zone, a signal of elevated financial risk.

Creative Medical Technology Holdings, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 27.6% below estimates on average.

Wall Street analysts project Creative Medical Technology Holdings, Inc. revenue of about $23.4M for fiscal 2026, with EPS near $-1.18.

The most recent 12 insider filings for Creative Medical Technology Holdings, Inc. break down as 2 sales and 10 purchases. On net that is roughly 47K shares acquired (about $17K) — insiders putting money in tends to read as conviction.

CELZ Financials

CELZ Latest News

CELZ Analyst Consensus

CELZ MoonshotScore

CELZ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources